User:Mr. Ibrahem/Regadenoson

Mr. Ibrahem/Regadenoson

Clinical data
Trade names	Lexiscan, Rapiscan, others
Other names	CVT-3146, 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN US DailyMed: Regadenoson US FDA: Regadenoson
Routes of administration	Intravenous
Drug class	A2A adenosine receptor agonist
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Identifiers
IUPAC name 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine
Chemical and physical data
Formula	C15H18N8O5
Molar mass	390.360 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
InChI InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1 N Key:LZPZPHGJDAGEJZ-AKAIJSEGSA-N N
NY (what is this?)  (verify)

Regadenoson, sold under the brand name Lexiscan among others, is a medication used for pharmacologic stress testing. It is used as part of radionuclide myocardial perfusion imaging. It is given by injection into a vein.

Common side effects include dizziness, headache, ST segment changes, flushing, shortness of breath, and chest pain. Other side effects may include seizures and anaphylaxis. It should not be used in people with low blood pressure or poorly controlled heart failure. It is an A_2A adenosine receptor agonist which results in vasodilation of blood vessels to the heart.

Regadenoson was approved for medical use in the United States in 2008 and Europe in 2010. In the United States it costs about 270 USD per dose as of 2021.